BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced the results of multiple studies presented at the 45th American Society of Clinical Oncology meeting between May 30 and June 1, 2009 in Orlando, Florida. Key posters and presentations by clinical oncologists from around the world included studies of REVLIMID in multiple myeloma, several forms of non-Hodgkin’s lymphoma and prostate cancer; VIDAZA in myelodysplastic syndromes and Amrubicin in small cell lung cancer. These data continue to support the activity demonstrated in previous studies.
